Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 3/20 | 0.58 |
| ▸ | DRD4 | P21917 | 3/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.58 |
| ▸ | ACHE | P22303 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264074 | 0.91 | RECQL (0.52) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL1264072 | 0.91 | RECQL (0.52) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL2087518 | 0.89 | RECQL (0.60) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL3709310 | 0.85 | RECQL (0.70) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL3319068 | 0.85 | KMT2A (0.68) | DRD4ACHESIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL3706762 | 0.83 | RECQL (0.68) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL13990656 | 0.83 | L3MBTL3 (0.68) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL3285312 | 0.83 | DRD2 (0.65) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| SCHEMBL3956954 | 0.83 | MC4R (0.69) | RECQLSMN1; SMN2DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL4324912 | 0.82 | DRD2 (0.63) | RECQLSMN1; SMN2DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| CN-101835779-B | Purine derivatives useful as PI3 kinase inhibitors | HOFFMANN LA ROCHE | 2014-01-29 | — | — | CN | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
| EP-2215090-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009053716-A1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | RECQL 531/4885SMN1; SMN2 2854/4885DRD2 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.